Hercules Capital Provides $125MM Term Loan Facility to Provention Bio

Provention Bio, a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, secured a term loan facility of up to $125 million with Hercules Capital.

September 1, 2022 Bryan Jadot | Hercules Capital | Jefferies | Provention Bio Ian Koplin

Hercules Capital Enters into $50MM Term Loan Agreement with Alladapt Immunotherapeutics

Alladapt Immunotherapeutics, a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, entered into a term loan agreement for up to $50 million with Hercules Capital.

August 31, 2022 Alladapt Immunotherapeutics | Armentum Partners | Cristy Barnes | Glenn Reicin | Hercules Capital | Himani Bhalla Ian Koplin

Hercules Capital Provides $175MM Term Loan to atai Life Sciences

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, entered into a term loan facility for up to $175 million with Hercules Capital.

August 16, 2022 atai Life Sciences | Hercules Capital | Janice Bourque | Latham & Watkins | Michael Dutra | Morrison & Foerster Ian Koplin

Hercules Capital and Silicon Valley Bank Provide $80MM Credit Facility for Gritstone bio

Gritstone bio, a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, entered into an $80 million credit facility with Hercules Capital and Silicon Valley Bank.

July 22, 2022 Andrew Allen | Capital Advisors Group | Celia Economides | Cristy Barnes | Gritstone bio | Hercules Capital | Himani Bhalla | Michael White | Silicon Valley Bank Ian Koplin

Hercules Capital Expands Credit Facility with MUFG Bank and SMBC to $720MM

Hercules Capital increased its existing credit facilities with MUFG Bank and Sumitomo Mitsui Banking Corporation from a combined $500 million to $720 million, subject to a borrowing base, leverage and other restrictions. 

June 16, 2022 City National Bank | Goldman Sachs | Hercules Capital | MUFG Bank | Seth Meyer | Sumitomo Mitsui Banking Corporation | Synovus Financial Corporation Ian Koplin

Hercules Capital Provides $75MM Credit Facility to Viridian Therapeutics

Viridian Therapeutics, a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, entered into a debt financing agreement with Hercules Capital for up to $75 million.

April 5, 2022 Cristy Barnes | Hercules Capital | Kristian Humer | Viridian Therapeutics Ian Koplin

Hercules Capital Expands TG Therapeutics’ Term Loan to $200MM

Hercules Capital amended TG Therapeutics’ existing term loan facility agreement to increase the size of the facility to $200 million, with $70 million funded at closing.

January 5, 2022 Hercules Capital | Michael Dutra | Michael S. Weiss | TG Therapeutics Ian Koplin

Hercules Capital Surpasses $2B in Annual Gross Debt and Equity Commitments

Hercules Capital has originated more than $2 billion year to date in annual total gross debt and equity commitments, breaking its previous one-year record of $1.47 billion.

November 29, 2021 Hercules Capital | Scott Bluestein Ian Koplin

SMBC Provides $100MM Multi-Currency Credit Facility to Hercules Capital

Hercules Capital, a specialty financing provider to companies backed by venture capital and select private equity firms, entered into a $100 million multi-currency credit facility with Sumitomo Mitsui Banking Corporation.

November 11, 2021 Hercules Capital | Seth Meyer | Sumitomo Mitsui Banking Corporation Ian Koplin

Hercules Capital Provides $25MM Credit Facility to Locus Biosciences

Locus Biosciences, a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for bacterial and inflammatory diseases, entered a credit facility of up to $25 million with Hercules Capital.

October 20, 2021 Bryan Jadot | Hercules Capital | Locus Biosciences | Paul Garofolo Ian Koplin